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Abstract: Cognitive decline is associated with lifestyle-related factors such as overweight,
blood pressure, and dietary composition. Studies have reported beneficial effects of dietary
anthocyanins on cognition in older adults and children. However, the effect of anthocyanin-rich
Aronia melanocarpa extract (AME) on cognition is unknown. Therefore, this study aimed to determine
the effect of long-term supplementation with AME on cognitive performance, mood, and vascular
function in healthy, middle-aged, overweight adults. In a randomized double-blind placebo-controlled
parallel study, 101 participants either consumed 90 mg AME, 150 mg AME, or placebo for 24 weeks.
The grooved pegboard test, number cross-out test, and Stroop test were performed as measures for
psychomotor speed, attention, and cognitive flexibility. Mood was evaluated with a visual analogue
scale, serum brain-derived neurotrophic factor (BDNF) was determined, and vascular function was
assessed by carotid ultrasounds and blood pressure measurements. AME improved psychomotor
speed compared to placebo (90 mg AME: change = −3.37; p = 0.009). Furthermore, 150 mg AME
decreased brachial diastolic blood pressure compared to 90 mg AME (change = 2.44; p = 0.011),
but not compared to placebo. Attention, cognitive flexibility, BDNF, and other vascular parameters
were not affected. In conclusion, AME supplementation showed an indication of beneficial effects on
cognitive performance and blood pressure in individuals at risk of cognitive decline.
Keywords: polyphenols; anthocyanins; black chokeberry; cyanidin-3-glycosides; brain health;
cognition; BDNF; human; overweight
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1. Introduction
Cognitive decline is normal and inevitable age-associated deterioration of cognitive performance,
which is implicated in the development of neurodegenerative diseases such as dementia [1].
Gradual degradation of cognitive functions commences in early adulthood and starts progressing more
rapidly during mid-life [2]. In addition, several lifestyle-related risk factors such as overweight status,
smoking, high blood pressure and diet, but also genetic factors are associated with a more pronounced
rate of cognitive decline [3,4]. Around 15–20% of individuals aged over 60 years old present with mild
cognitive impairment, a condition which alters their ability to learn new information or to recall stored
information, without severe impairments in daily functioning [5]. There is increasing evidence that
these individuals have a greater risk of developing more serious cognitive impairment or ultimately
even dementia [6]. Considering the ageing population, it is apparent that the incidence of individuals
who will suffer from the consequences associated with cognitive impairment will increase. It is foreseen
that the number of dementia patients will triple by 2050 [7]. Currently, there are no medications or
treatments for neurodegenerative disorders. Therefore, there is an urgent need to develop strategies to
delay or even prevent the onset of cognitive impairment.
Anthocyanins are a subgroup of polyphenols mainly found in berries, recognized for their
health benefits [8]. Anthocyanins and their associated compounds such as cyanidin-3-glycosides
cross the blood-brain barrier, where they are able to suppress neuroinflammation and oxidative
stress [9,10]. These functionalities are thought to be attributable to modulation of pro-inflammatory
signaling pathways, direct scavenging of reactive oxygen species, and indirect enhancement of
antioxidant defenses [11]. Currently, dietary recommendations concerning anthocyanins are not
available. However, total daily intake of fruits and vegetables known to be rich in anthocyanins in
North America, Europe, and Oceania appeared to be lower than the nutritional recommendations [12].
Furthermore, it was observed that berries comprised only 10% of daily fruit intake, in a health
and nutrition survey among Americans [13]. Consequently, supplementation could be an approach
to increase anthocyanin intake. A high content of cyanidin-3-glycoside anthocyanins is found in
black chokeberries (e.g., Aronia melanocarpa). Over the last few years, protective effects of Aronia
melanocarpa regarding chronic diseases such as gastrointestinal diseases, diabetes, cardiovascular
diseases, and cancer have been studied [10]. In a recent systematic review by Kent et al. [14],
multiple human intervention studies with a beneficial effect of food-derived anthocyanins on both
acute and long-term cognition were reported. Most of these studies focus on younger children or
older adults who already experience (mild) cognitive impairment. In addition, multiple factors
have been suggested as potential contributors to cognitive performance, such as increased levels of
brain-derived neurotrophic factor (BDNF) [15,16] and improved vascular health [17,18]. However,
studies investigating the effect of anthocyanin-rich Aronia extracts on cognition as well as exploring
potential underlying mechanisms such as BDNF and vascular function are still lacking, with only a few
animal studies available [19–21]. Accordingly, the primary aim of this study was to determine the effect
of long-term supplementation with an anthocyanin-rich Aronia melanocarpa extract (AME) on cognitive
performance and mood in healthy, middle-aged, overweight adults. This population was chosen since
both age and overweight status are associated with increased risk of cognitive decline [2,4]. In addition,
the effect of Aronia melanocarpa extract supplementation on vascular function and BDNF concentrations
was explored, as potential mechanisms associated with changes in cognitive function.
2. Materials and Methods
The study was performed at the Metabolic Research Unit Maastricht (MRUM) of the Maastricht
University from February 2017 until August 2018. This study was approved by the local Medical Ethics
Committee and performed in accordance with the Declaration of Helsinki. All participants gave written
informed consent before data collection. The study has been registered in 2017 at clinicaltrials.gov
as NCT03236259.
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2.1. Study Participants
113 healthy adults aged 40–60 years, with a body mass index (BMI) between 25 and 35 kg/m2
were recruited through local advertisements (Figure S1). Exclusion criteria included major surgery
or history of chronic diseases such as cardiovascular disease, which might influence participation
or completion of the entire study protocol; use of medication that might influence endpoints of this
study, such as high blood pressure medication; vitamin, mineral, or antioxidant supplementation;
pregnancy; smoking; alcohol abuse (>20 alcoholic units/week); drug use; and intake of dietary products
containing anthocyanins during the study. In total, 102 participants were included in the study of
which 97 completed the entire study protocol (Figure S1). One participant never started the protocol
after screening and randomization due to personal reasons. Three participants dropped out of the
study as a result of starting new medication that was prescribed during the study, which would have
interfered with the outcomes of the study, and one participant stopped due to personal reasons.
2.2. Study Design
The study was designed as a randomized double-blind placebo-controlled parallel study
to determine the effect of 24 weeks of daily supplementation with AME compared to placebo.
After screening, participants were randomly allocated to groups of either 90 mg Aronia melanocarpa,
150 mg Aronia melanocarpa, or the placebo group. Randomization was performed by an independent
person, by use of Research Randomizer (http://randomizer.org), using concealed and random block sizes.
At baseline, after 6, 12, and 24 weeks of intervention, anthropometric measurements, cognitive tests,
mood questionnaires, and ultrasounds of the carotid artery were performed and blood was sampled.
At the start of the study, participants were provided with a list of food products containing high
anthocyanin content (black chokeberry, blueberry, blackcurrant, elderberry, cranberry, strawberry,
raspberry, plums, red grape, red cabbage, cherry, eggplant, jam or juice from any of these components,
green tea, and vitamin preparations/nutritional supplements) and were instructed to abstain from
these products during the entire study period. In addition, participants were instructed to refrain from
vigorous physical exercise two days prior to each test day. Compliance was assessed by means of a
daily supplementation log and all remaining capsules were handed in by the participants after the
study period was completed.
2.3. Study Product
The product used in this study is anAronia melanocarpa extract (AME) containing 18% anthocyanins
(Brainberry®, BioActor BV, Maastricht, The Netherlands). These anthocyanins consist of several
cyanidin-3-glycosides, mostly cyanidin-3-galactoside, cyanidin-3-arabinoside, cyanidin-3-xyloside,
and cyanidin-3-glucoside [22]. The 150 mg AME capsule consisted of 27 mg anthocyanins (150 mg
Brainberry®) and the 90 mg AME capsule consisted of 16 mg anthocyanins (90 mg Brainberry®)
and 60 mg maltodextrin (Gonmisol, Barcelona, Spain). Maltodextrin containing capsules (150 mg)
were used as placebo. Participants were instructed to ingest one capsule daily before breakfast,
with 200 mL water.
2.4. Cognitive and Mood Assessments
During each test day, three different cognitive tests were performed in the same order: the Stroop
color and word test, the grooved pegboard test, and the number cross-out test. These tests assess three
different aspects of cognitive behavior, i.e., cognitive flexibility, psychomotor speed, and attention,
respectively. Mood was also assessed using the visual analogue mood scale.
The Stroop color and word test comprised three cards: names of colors in black ink,
colored rectangles, and names of colors in non-corresponding ink color [23]. The goal was to
read out the colors for the first two cards. However, on the third card, the ink color had to be named as
quickly and precisely as possible. Using the time needed to complete the third card minus the time
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needed to complete the second card, a final score, the Stroop interference score, could be determined.
Participants were checked for color-blindness prior to this test.
The grooved pegboard test consisted of a board with 25 pegs and randomly positioned slots,
and was executed first with the dominant hand, followed by the non-dominant hand. The time needed
to complete the test, the number of pegs that were accidentally dropped, and the amount of correctly
placed pegs within the 5-min time limit were recorded to obtain on overall score for each hand [24].
The number cross-out test is a validated test in which specific numbers on a card containing 800
numbers must be crossed out or underlined within a 3-min time limit [25]. The amount of correctly,
incorrectly, edited, and missed crossed and underlined numbers was used to calculate two scores for
attention: (1) total correct—total incorrect (accuracy) and (2) total edited—total incorrect and missed
(diligence). These scores were corrected for age to obtain percentile scores.
Mood was determined by means of a visual analogue mood scale, a tool developed for repeatedly
assessing self-reported mood states in clinical research [26]. Eight mood states were included: afraid,
angry, confused, energetic, happy, sad, tense, and tired. On a card, a 100 mm line connected the word
‘neutral’ to one of these mood states. Subsequently, the participants drew a line at the point that best
described how they were feeling at that moment. The distance from the word neutral was measured
and represented the level of that mood. From these scores, a T-score could be determined, based on
age and gender.
2.5. Vascular Assessments
Carotid ultrasound and blood pressure examinations were carried out at each visit by a trained
and certified researcher. Participants were examined in a reclined position, after at least 15 min of rest.
Carotid movement (M)- and brightness (B)-mode ultrasound scans of the right and left common arteries
were performed with a Sonix Touch Instrument with a 7.5 MHz transducer (Analogic Corporation,
Peabody, MD, USA). All scan and image analyses have been described previously [27,28]. In short,
M-mode ultrasound scans depicted near and far wall movements of the distal common carotid artery
for at least three consecutive heartbeats. B-mode ultrasound scans were carried out to depict 1 cm of
the common carotid artery proximal to the carotid bulb. M- and B-mode images were transferred for
immediate quality control (Imagelabonline and Cardiovascular, Erichem, The Netherlands). For image
analyses, eTrack software (Sonix Touch version) was used by an analyst blinded for timepoints
and treatments [29]. M-mode images provided the arterial elastic modulus of Peterson (eP) data.
From B-mode images, mean and maximal distances between the lumen-intima and media-adventitial
layers in the far wall, carotid intima-media thickness (cIMT) were determined.
Simultaneous double-arm blood pressure (BP) measurements and ankle-brachial index (ABI)
assessments were performed using the validated automated oscillometric WatchBP Office Central
(Microlife Corp., Taipei, Taiwan) [30,31]. ABI was calculated by the device as the quotient of the
brachial systolic BP and the higher BP of the anterior or posterior tibial artery. In addition, the BP of the
ascending aorta was assessed non-invasively (central BP). For this, the monitor transforms peripheral
pulse waves to central BP using an individual-based pulse wave analysis.
2.6. Biochemical Analysis
During each test day, blood was collected in serum separator tubes (BD Vacutainer, NJ,
USA). After complete coagulation, samples were centrifuged (room temperature, 1300× g, 10 min).
Serum aliquots were stored for further analysis at the end of the trial. Brain-derived neurotrophic
factor (BDNF) levels were determined in samples of weeks 0, 6, 12, and 24, using a commercially
available sandwich enzyme-linked immunosorbent assay (ELISA) kit, according to the manufacturer’s
protocol (Duoset, R&D systems, Bio-techne, Minneapolis, MN, USA). Additionally, at the start
(week 0) and at the end of the study (week 24), concentrations of alanine aminotransferase (ALT),
alkaline phosphatase (ALP), bilirubin, and gamma-glutamyl transferase (GGT) in serum were
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determined as an indication for liver function using spectrophotometry (Cobas 8000 analyzer series,
Roche Diagnostics, Mannheim, Germany).
2.7. Statistical Analysis
Sample size was determined using a significance level of α = 0.017, a power of β = 0.80, and a
change in the trail making test A reaction time (measure of cognitive flexibility) of 7.8 s with a pooled
SD of 9.0, based on a study by Mastroiacovo et al. [32]. A sample size of n = 105 (i.e., 35 participants
per group), including a 15% drop-out rate, was calculated. Statistical analyses were conducted
using IBM SPSS Statistics (version 26.0, IBM Corporation, Armonk, NY, USA). One-way analyses of
variance (ANOVA) were carried out to assess study population demographics. Data were reported
as actual mean ± standard error of the mean (SEM). Furthermore, intention to treat analyses were
performed by linear mixed models with period, time (6, 12, and 24 weeks), and intervention as fixed
factors, time * intervention as interaction term, and with the baseline (0 weeks) value as covariate.
To compare placebo, 90 mg AME supplementation, and 150 mg AME supplementation the effect of
time, intervention, and the interaction were analyzed. If the interaction term was not significant, it was
omitted from the model. If the factor time or treatment was significant, post hoc tests with correction
for multiple comparisons were conducted. For all analyses, two-sided p values ≤ 0.05 were considered
statistically significant.
3. Results
3.1. Inclusion and Population Demographics
Baseline characteristics of all three groups are presented in Table 1. At baseline, the groups were
comparable regarding gender distribution, age, BMI, cognitive performance, and blood pressure.
AME supplementation was well tolerated by participants and did not display changes in liver function
as assessed by the measure of ALT, ALP, bilirubin, and GGT in serum following 24 weeks of AME
intake. All measures remained stable and within normal physiological ranges (Table S1) [33].






(n = 32) p-Value
Male Gender (n; %) 11; 32% 11; 31% 14; 44% 0.510
Age (years) 53 ± 1 53 ± 1 53 ± 1 0.722
BMI (kg/m2) 29.5 ± 0.4 29.4 ± 0.5 29.3 ± 0.5 0.988
Pegboard dominant hand score 2 94.4 ± 1.6 97.3 ± 2.1 92.9 ± 2.0 0.244
Pegboard non-dominant hand score 2 98.1 ± 2.0 103.9 ± 2.0 100.4 ± 2.1 0.125
Total correct—total incorrect 3 47.2 ± 4.7 54.5 ± 4.9 55.4 ± 5.6 0.461
Total edited—total incorrect and missed 3 49.1 ± 4.7 54.8 ± 4.7 55.6 ± 5.8 0.615
Stroop Interference (sec) 2 32.7 ± 2.0 31.5 ± 2.7 30.7 ± 1.9 0.833
Brachial systolic blood pressure
(mm Hg)
130.0 ± 2.6 130.1 ± 2.1 131.4 ± 2.6 0.896
Brachial diastolic blood pressure (mm Hg) 81.3 ± 1.5 81.2 ± 1.3 82.2 ± 1.4 0.873
1 Data is displayed as actual mean ± standard error of the mean (SEM) or as percentage. Analysis was performed
with one-way analysis of variance (ANOVA). 2 Lower scores indicate a better performance. 3 Higher scores indicate
a better performance, expressed as a percentile. BMI: body mass index.
3.2. Aronia melanocarpa Extract Improves Psychomotor Speed, but Does Not Affect Attention, Cognitive
Flexibility, Mood, and Serum Brain-Derived Neurotrophic Factor (BDNF) Levels
The overall time*treatment interaction for the dominant hand score of the grooved pegboard test
was not significant (p = 0.998). Interestingly, a significant treatment effect (p = 0.033) was observed after
omitting the interaction term from the model. After correction for multiple testing, the 90 mg AME
group had a significantly improved score compared to placebo (change = −3.37; p = 0.009) (Figure 1).
No differences could be observed between 150 mg AME and placebo, and between 150 mg AME and
90 mg AME. In addition, a main effect of time was observed (p < 0.05). Post hoc analyses revealed an
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overall time effect: 95.0 at baseline, 91.1 after 6 weeks, 89.8 after 12 weeks, and 88.0 after 24 weeks.
The combined mean of time at 6 weeks was significantly higher compared to the mean after 24 weeks
(p < 0.05).
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Figure 1. The effect of Aronia melanocarpa extract (AME) supplementation on psychomotor speed
of the dominant and non-do inant hand. Data are presented as actual mean ± SEM. Analysis was
performed with a linear ixed model using estimated means, with correction for baseline values.
Post hoc analyses were perfor ed for the factor time*treatment, treatment, or time, where applicable.
Statistically significant differences between two timepoints are denoted by the letter a. Lower scores
indicate better performance.
Regarding the non-dominant hand, an overall time*treatment interaction was observed (p = 0.016).
However, after correction for multiple te ting, there were no significant differences for the non-dominant
hand (Figure 1).
Regarding the domain attention, assessed w th the number cross-out test, the time*treatment
interaction was not significant f the total correct–total incorrec (p = 0.287) and the total edited–t tal
incorr ct and missed (p = 0.196). A t r omitting the i t raction from th model, only the factor time
remained significant for both scores (p < 0.05) (Figure 2). For total correct–total incorrect, p st hoc
analyse revealed an overall time effect: 52.1 at baseline, 64.4 after 6 weeks, 68.9 fter 12 weeks, and 69.4
after 24 week . The combined me n of time at 6 weeks was significantly lower compared to after
12 weeks (p < 0.05) and after 24 weeks (p < 0.05). Similarly, for total edited—total incorrect and missed,
post hoc nalyses revealed an overall tim effect: 52.7 at baseline, 65.2 after 6 weeks, 68.7 after 12 weeks,
and 69.7 after 24 weeks. The combined mean of time at 6 weeks was significantly lower from the mean
after 12 weeks (p < 0.05) and after 24 weeks (p < 0.05).
No significant interaction was observed for cognitive flexibility, as assessed with the Stroop color
and word test (p = 0.172). No treatment effect was observed (p = 0.773), but a main effect of time
was observed (p < 0.05) (Figure 3). Post hoc analyses revealed an overall time effect: 31.8 at baseline,
28.6 after 6 weeks, 26.5 after 12 weeks, and 26.5 after 24 weeks. The combined mean after 6 weeks was
significantly higher compared to after 12 weeks (p < 0.05) and after 24 weeks (p < 0.05).
No significant time*treatment effects were observed for mood scores (Table 2). After omitting the
interaction term, the treatment effect for sadness approached significance (p = 0.069), with slightly
lower perceived levels of sadness after 150 mg AME compared to the placebo. Furthermore, for the
mood angry, the time effect approached significance (p = 0.051).
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Table 2. The effect ofAronia melanocarpa extract supplementation on mood scores afraid, angry, confused,
energetic, happy, sad, tense, and tired. 1







Afraid 0.881 a 0.191 b 0.301 b
Baseline 45.1 ± 0.9 45.1 ± 0.9 45.0 ± 0.7
6 weeks 46.1 ± 1.2 45.1 ± 0.7 47.3 ± 1.1
12 weeks 46.0 ± 1.2 45.9 ± 1.5 48.5 ± 1.7
24 weeks 44.8 ± 0.4 45.0 ± 0.5 45.9 ± 0.9
Angry 0.700 a 0.051 b 0.115 b
Baseline 44.0 ± 1.1 43.3 ± 0.3 44.0 ± 0.6
6 weeks 43.8 ± 0.3 43.5 ± 0.3 47.0 ± 1.4
12 weeks 44.8 ± 0.8 44.6 ± 1.3 46.3 ± 1.5
24 weeks 45.2 ± 0.8 44.5 ± 0.7 45.5 ± 1.4
Confused 0.392 a 0.463 b 0.231 b
Baseline 45.5 ± 1.5 43.7 ± 0.7 45.1 ± 1.2
6 weeks 45.2 ± 0.9 43.7 ± 0.4 44.9 ± 0.8
12 weeks 44.2 ± 0.5 44.6 ± 1.3 47.3 ± 1.8
24 weeks 45.8 ± 1.9 44.5 ± 0.7 46.0 ± 1.5
Energetic 0.306 a 0.183 b 0.632 b
Baseline 44.5 ± 2.0 45.1 ± 2.2 47.1 ± 2.0
6 weeks 44.6 ± 2.3 44.7 ± 2.1 40.9 ± 2.3
12 weeks 47.2 ± 2.2 44.1 ± 2.1 46.6 ± 2.8
24 weeks 44.8 ± 1.9 43.9 ± 2.1 44.6 ± 2.4
Happy 0.119 a 0.112 b 0.366 b
Baseline 41.9 ± 2.2 43.3 ± 2.3 42.9 ± 2.8
6 weeks 41.0 ± 2.6 40.7 ± 2.5 36.8 ± 2.4
12 weeks 46.5 ± 2.1 41.0 ± 2.7 39.5 ± 2.7
24 weeks 41.0 ± 2.3 42.0 ± 2.4 41.8 ± 2.5
Sad 0.976 a 0.600 b 0.069 b
Baseline 44.3 ± 1.0 43.7 ± 0.7 43.4 ± 0.5
6 weeks 45.9 ± 1.3 43.7 ± 0.6 45.8 ± 1.3
12 weeks 45.7 ± 1.2 44.4 ± 1.5 47.1 ± 1.7
24 weeks 45.8 ± 1.1 44.1 ± 0.7 45.2 ± 1.4
Tense 0.974 a 0.318 b 0.156 b
Baseline 45.4 ± 1.2 45.6 ± 1.3 44.0 ± 0.9
6 weeks 43.9 ± 1.1 43.6 ± 0.7 45.3 ± 1.2
12 weeks 43.9 ± 0.9 43.9 ± 1.3 44.6 ± 1.5
24 weeks 43.4 ± 1.1 42.7 ± 0.6 44.6 ± 1.4
Tired 0.169 a 0.379 b 0.318 b
Baseline 43.8 ± 1.1 44.4 ± 1.4 41.1 ± 1.1
6 weeks 44.1 ± 1.5 45.0 ± 1.6 44.5 ± 1.4
12 weeks 47.2 ± 1.6 45.0 ± 1.6 44.5 ± 1.3
24 weeks 45.4 ± 1.5 43.5 ± 1.3 45.6 ± 1.8
1 Data are presented as actual mean ± SEM. Analysis was performed with a linear mixed model using estimated
means, with correction for baseline values. a p-values originate from the linear mixed model with a time*treatment
interaction. b p-values originate from the linear mixed model without a time*treatment interaction.
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No significant time*treatment effects were observed for mood scores (Table 2). After omitting 
the interaction term, the treatment effect for sadness approached significance (p = 0.069), with slightly 
lower perceived levels of sadness after 150 mg AME compared to the placebo. Furthermore, for the 
mood angry, the time effect approached significance (p = 0.051). 
Table 2. The effect of Aronia melanocarpa extract supplementation on mood scores afraid, angry, 
confused, energetic, happy, sad, tense, and tired. 1 
Mood (T-
Scores) 
90 mg Aronia 
(n = 34) 
150 mg Aronia 
(n = 35) 
Placebo 
(n = 32) 
Time*Treatment 
Interaction 
Main Effect of 
Time 
Main Effect of 
Treatment 
Afraid    0.881 a 0.191 b 0.301 b 
Baseline 45.1 ± 0.9 45.1 ± 0.9 45.0 ± 0.7    
6 weeks 46.1 ± 1.2 45.1 ± 0.7 47.3 ± 1.1    
12 weeks 46.0 ± 1.2 45.9 ± 1.5 48.5 ± 1.7    
24 weeks 44.8 ± 0.4 45.0 ± 0.5 45.9 ± 0.9    
Angry    0.700 a 0.051 b 0.115 b 
Baseline 44.0 ± 1.1 43.3 ± 0.3 44.0 ± 0.6    
6 weeks 43.8 ± 0.3 43.5 ± 0.3 47.0 ± 1.4    
12 weeks 44.8 ± 0.8 44.6 ± 1.3 46.3 ± 1.5    
24 weeks 45.2 ± 0.8 44.5 ± 0.7 45.5 ± 1.4    
Confused    0.392 a 0.463 b 0.231 b 
Baseline 45.5 ± 1.5 43.7 ± 0.7 45.1 ± 1.2    
6 weeks 45.2 ± 0.9 43.7 ± 0.4 44.9 ± 0.8    
12 weeks 44.2 ± 0.5 44.6 ± 1.3 47.3 ± 1.8    
24 weeks 45.8 ± 1.9 44.5 ± 0.7 46.0 ± 1.5    
Energetic    0.306 a 0.183 b 0.632 b 
Baseline 44.5 ± 2.0 45.1 ± 2.2 47.1 ± 2.0    
6 weeks 44.6 ± 2.3 44.7 ± 2.1 40.9 ± 2.3    
12 weeks 47.2 ± 2.2 44.1 ± 2.1 46.6 ± 2.8    
24 weeks 44.8 ± 1.9 43.9 ± 2.1 44.6 ± 2.4    
Happy    0.119 a 0.112 b 0.366 b 
Baseline 41.9 ± 2.2 43.3 ± 2.3 42.9 ± 2.8    
6 weeks 41.0 ± 2.6 40.7 ± 2.5 36.8 ± 2.4    
12 weeks 46.5 ± 2.1 41.0 ± 2.7 39.5 ± 2.7    
24 weeks 41.0 ± 2.3 42.0 ± 2.4 41.8 ± 2.5    
Figure 3. The effect of Aronia melanocarpa extract (AME) supplementation on cognitive flexibility,
assessed with the Stroop color and word test. Data are presented as actual mean ± SEM. Analysis was
performed with a linear mixed model using estimated means, with correction for baseline values.
Post hoc analyses were performed for the factor time. Statistically significant differences between two
timepoints are denoted by the letter a or b. Lower scores indicate better performance.
Serum BDNF concentrations, which have been implicated as an important factor in cognitive
function [34], were determined at all time points. No significant time*treatment interaction was
observed (p = 0.804). The main effect of time (p = 0.164) or treatment (p = 0.940) also did not differ
(Figure 4).
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Data are presented as actual mean ± SEM. Analysis was performed with a linear mixed model using
estimated means, with correction for baseline values. BDNF: brain-derived neurotrophic factor
3.3. Aronia melanocarpa Extract Decreases Blood Pressure, but Does Not Affect Other Vascular Functions
After the cognitive test battery, vascular function parameters were assessed. No significant
time*treatment interactions were observed for carotid elasticity (eP) (p = 0.81 ), intima-media thickness
(cIMT) (p = 0.723), or ABI (p = 0.612), see Table 3. After omitting the interaction term, no significant
time or treatment effects were observed.
Regarding blood pressure, for brachial systolic BP, no significant time*treatment interaction
(p = 0.554), treatment effect (p = 0.788), or time effect (p = 0.451) w s observed. For brachial diastolic BP,
after omitting the interaction term (p = 0.098), a significant treatment effect (p = 0.025) was observed.
Post hoc analyses revealed a significant difference between 90 mg AME and 150 mg AME (change = 2.44;
p = 0.011) (Figure 5). Furthermore, the difference between placebo and 150 mg AME approached
significance (change = 1.437; p = 0.073). For the other parameters (central diastolic and systolic BP,
and max cIMT), no statistically significant differences were observed (Table S2).
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Table 3. The effect of Aronia melanocarpa extract (AME) supplementation on arterial elasticity,
intima-media thickness, and ABI 1.







eP (kPa) 0.810 a 0.908 b 0.165 b
Baseline 75.6 ± 4.8 62.4 ± 3.6 65.9 ± 3.0
6 weeks 65.7 ± 3.4 62.1 ± 2.0 63.8 ± 3.0
12 weeks 65.4 ± 3.7 67.2 ± 3.8 60.3 ± 2.9
24 weeks 67.0 ± 3.3 64.1 ± 2.4 60.0 ± 3.3
cIMT Mean (mm) 0.723 a 0.326 b 0.328 b
Baseline 0.64 ± 0.01 0.63 ± 0.02 0.64 ± 0.01
6 weeks 0.62 ± 0.02 0.64 ± 0.01 0.64 ± 0.02
12 weeks 0.63 ± 0.02 0.64 ± 0.01
24 weeks 0.62 ± 0.02 0.65 ± 0.02 0.65 ± 0.02
ABI 0.612 a 0.973 b
Baseline 1.23 ± 0.02 1.21 ± 0.01 1.23 ± 0.02
6 weeks 1.24 ± 0.02 1.23 ± 0.02 1.25 ± 0.02
12 weeks 1.26 ± 0.02 1.24 ± 0.02 1.23 ± 0.02
24 weeks 1.27 ± 0.02 1.25 ± 0.02 1.26 ± 0.02
1 Data are presented as actual mean± SEM. Analysis was performed with a linear mixed model using estimated means,
with correction for baseline values. Lower eP and cIMT values indicate better arterial health. a p-values originate from
the linear mixed model with a time*treatment interaction. b p-values originate from the linear mixed model without
a time*treatment interaction. ABI: ankle-brachial index; eP: arterial elasticity; cIMT: carotid intima-media-thickness.
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Figure 5. The effect of Aronia melanocarpa extract (AME) supplementation on brachial systolic and
diastolic blood pressure. Data are presented as actual mean ± SEM. Analysis was performed with a
linear mixed model using estimated means, with correction for baseline values. Post hoc analyses were
performed for the factor treatment where applicable.
4. Discussion
In this study, the effects of 24 weeks of supplementing an Aronia melanocarpa extract (AME)
rich in anthocyanins on cognitive performance and mood in middle-aged overweight adults were
assessed. Furthermore, effects of this supplementation on BDNF and vascular function were explored.
We observed a significant treatment effect of 90 mg AME supplementation indicating better performance
on one aspect of cognition: psychomotor speed, as compared to placebo. Furthermore, a treatment
effect indicating lower brachial diastolic blood pressure after 150 mg AME supplementation was
observed compared to 90 mg AME, but not compared to placebo. No effects of AME supplementation
could be shown regarding attention, cognitive flexibility, mood, serum BDNF concentrations, and the
other vascular parameters.
To our knowledge, this is the first human intervention study evaluating the effects of AME
supplementation, using an anthocyanin-rich Aronia extract, on cognition. Cognitive performance
is a broad concept, encompassing multiple complex processes which can be categorized into six
main domains: attention, executive function, perceptual-motor function, language, learning and
memory, and social cognition [35]. We focused on the first three domains by assessing the subdomains
psychomotor speed, attention, and cognitive flexibility, which are often assessed in similar study
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populations [25,36,37]. Here, we showed that AME supplementation selectively enhanced one out of
three of these areas. Supplementation with 90 mg AME resulted in a higher score for psychomotor
speed of the dominant hand, compared to placebo, whilst no significant treatment effect was observed
for 150 mg AME. The non-dominant hand scores did not differ between both AME groups, compared to
placebo. Previous studies have reported improvements in both hands after strength training in healthy
elderly people [38] and music training in children [39], focusing more particularly on hand dexterity.
Nevertheless, different outcomes for both hands have also been observed in studies determining
motor function following sleep deprivation among medical personnel [40] and after an intravenous
delta-9-tetrahydrocannabinol challenge [41]. Inconsistent with our results, these two latter studies
reported statistically significant alterations for the non-dominant hand, but not for the dominant hand.
Even though we did observe an effect of time in our study, indicating a practice effect, it must be taken
into account that the studies mentioned above were acute and short-term. Consequently, they may
have faced a greater practice effect due to repetitions within a shorter follow up time as compared to
our longer-term chronic study.
In contrast to the first cognitive test, no effect of AME supplementation on accuracy and cognitive
flexibility was observed. Keeping this in mind, it could be proposed that AME affects specific processes
or mechanisms involved in cognition. Some human studies suggest that BDNF is associated with
cognitive function [15,42,43]. BDNF is a protein which has been implicated as a promotor of neuronal
cell survival and plasticity, which is crucial for cognitive functioning [44]. A study in aged rats reported
a favorable effect of blueberry flavonoids on hippocampal BDNF levels, which correlated to improved
cognitive function [45]. Moreover, increased BDNF serum levels in relation to improved cognitive
performance have also been observed in healthy adults after consuming a high-flavonoid diet [16].
However, similar to our study, others did not report a relationship between BDNF and cognition [46,47].
Contradictory results between these studies might be explained by the different tests and domains
used to assess cognitive function. Furthermore, next to BDNF there are other biological factors known
to be involved with cognitive function. For example, dopamine has been recognized as an important
factor in cognitive performance [48]. For example, in ageing mice brain tissue, increased dopamine
levels were observed after supplementation with Aronia melanocarpa [19]. Interestingly, serum levels
of dopamine metabolites were recently found to be negatively associated with cognitive impairment
in Parkinson’s disease patients [49]. Furthermore, supplementation with berry anthocyanins in rats
resulted in increased hippocampal insulin-like growth factor (IGF)-1 expression [50]. In addition,
human studies have reported an association of serum IGF-1 with cognitive function in middle aged
and elderly individuals [51,52]. However, obesity is known to result in impaired IGF-1 signaling [53],
and circulating IGF-1 levels have been shown to be dysregulated in obesity [54]. Moreover, cognitive
performance is generally worse in obese individuals compared to healthy individuals [4]. Given these
apparent inconsistencies, IGF-1 may not be a likely candidate for our overweight study population.
Instead, an improvement in vascular function remains the most likely explanation.
Multiple anthocyanin studies have shown to improve measures of cognitive function and vascular
health [17,18], suggesting that vascular function might be a mechanism involved in cognitive
improvement. However, in this study, we did not observe an effect of AME supplementation
on any of the analyzed vascular parameters, compared to placebo. Interestingly, we did observe a
treatment effect regarding brachial diastolic blood pressure. Post hoc analysis revealed lower brachial
diastolic blood pressure in the 150 mg AME group compared to the 90 mg AME group, but not with
placebo. Studies regarding berry-derived anthocyanin supplementation on vascular health have shown
conflicting results, depending on the assessment of vascular function [55]. Specifically, most beneficial
results were observed after flow mediated dilation, pulse wave velocity, and the reactive hyperemia
index [55,56]. Moreover, a recent study with Aronia melanocarpa observed an increase in flow-mediated
dilation, but not on peripheral and central blood pressure and arterial stiffness [57]. When looking
at the vascular parameters assessed in this study, cIMT was comparable to values observed in other
studies using similar populations [58]. Currently, available data on arterial stiffness are focused on
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either young adults with low eP values [59], or patients suffering from cardiovascular disease with high
eP values [60], making it difficult to interpret our outcomes properly. Consequently, other methods
of vascular functionality assessments may be more sensitive to assess effects of Aronia melanocarpa
supplementation and as such show the link between effects of AME on cognitive function via improved
vascular function.
Regarding mood, no effects of supplementation were observed. Currently, there is limited
evidence in literature for a beneficial effect of anthocyanin supplementation on mood, with some
studies describing trends towards improved alertness, calmness, and decreased fatigue [61,62].
Throughout the study, both AME groups and the placebo group showed improvements in all
three aspects of cognitive function (though more pronounced in the AME group), suggesting that no
cognitive decline in any of these areas was present in our study population and that a practice effect on
the cognitive tests occurred. To limit these issues, it would be interesting to further investigate the
effects of AME supplementation in a study population with more pronounced cognitive decline at
baseline. Indeed, Kent et al. [63] observed cognitive improvement after anthocyanin supplementation
in older adults with mild-to-moderate dementia, while there was no significant improvement in the
control group. Interestingly, the most prominent effects on cognition within our study were observed
after supplementation with 90 mg AME. This is not the first study that was unable to show a clear
dose response effect of anthocyanin supplementation. For example, a review evaluating various
flavonoid doses on vascular function did not observe any dose response relationships and found a
higher potency of lower doses [64]. In an in vitro study investigating the effect of Aronia melanocarpa
supplementation on reactive oxygen species-induced neuronal cell death, the low dose exerted a
protective effect, while high dose supplementation promoted superoxide-induced cell death [65].
However, the conditions used in this study were not physiological and, therefore, not comparable to
this study. Even though we also show a more potent effect of 90 mg AME supplementation, we did
not observe detrimental effects of 150 mg AME supplementation. Generally, the composition of
plant extracts has been shown to be extremely complex [66,67], and it might be possible that other
compounds in the extract alter the efficacy of the anthocyanins in Aronia melanocarpa. Therefore, we
hypothesize that a compound with a synergistic or inhibiting effect might be present within our extract.
The presence of a synergistic compound could result in increased effectivity of Aronia melanocarpa at
a low dose, but not at a higher dose (Figure 6, panel A). Similarly, an inhibiting compound could
negatively influence the effectiveness of Aronia melanocarpa at a higher dose, but not at a lower dose
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Limitations in the current study include the sole use of paper and pencil tests to establish cognitive
performance. Practice effects are often observed in studies assessing cognitive performance. Moreover,
recent studies have shown strong practice effects due to repetitive paper and pencil test taking [68,69].
These effects may have contributed to the improvements over time observed for all cognitive tests.
In order to correct for these practice effects, a placebo group was included in this study. To decrease
practice effects in future studies, other methods of cognitive testing could be used, e.g., the Cambridge
Neuropsychological Test Automated Battery (CANTAB), which is able to detect subtle age related
cognitive decline [70]. Another drawback in this study is that not all areas of cognition were assessed.
We chose to include only three domains in order to avoid a too high burden for participants which
might also influence the results, and to prevent a high number of cognitive parameters, which could
have made it difficult to draw a conclusion in the light of multiple testing issues. As a consequence, it is
impossible to state the effects of AME supplementation on full-term cognition. In addition, since this
study contained three groups, and four timepoints, correction for multiple testing had a massive impact
on the conclusions. Therefore, for a future study, limiting the amount of comparisons seems advisable.
Furthermore, participants were instructed to refrain from any products containing high anthocyanin
levels, which does not allow us to take potential synergistic effects of regular foods into account.
5. Conclusions
In conclusion, our results shown here are an indication that AME could have a protective effect
on cognition and blood pressure in healthy, middle-aged, overweight adults. Additionally, AME has
shown no effects on mood and other vascular functions, respectively. Further research is necessary to
elucidate the mechanism associated with the effect of Aronia melanocarpa on cognition, in populations
with more advanced cognitive decline.
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